# Anabolic Therapy in Postmenopausal Osteoporosis

> **NCT05010590** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 50 (actual)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** Romosozumab
- **DRUG:** Denosumab

## Key facts

- **NCT ID:** NCT05010590
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-24
- **Primary completion:** 2027-10-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05010590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05010590, "Anabolic Therapy in Postmenopausal Osteoporosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05010590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*